Sonova (OTCMKTS:SONVY) Reaches New 1-Year Low – What’s Next?

Sonova Holding (OTCMKTS:SONVY) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $43.51 and last traded at $43.57, with a volume of 1633 shares trading hands. The stock had previously closed at $44.79.

Analysts Set New Price Targets

SONVY has been the subject of a number of recent research reports. BNP Paribas Exane upgraded Sonova from a “strong sell” rating to a “strong-buy” rating in a research note on Tuesday, March 10th. Zacks Research raised shares of Sonova from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. Finally, Jefferies Financial Group cut shares of Sonova from a “hold” rating to a “moderate sell” rating in a research note on Wednesday, March 18th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Sonova Stock Performance

The company has a quick ratio of 0.91, a current ratio of 1.24 and a debt-to-equity ratio of 0.51. The firm has a 50 day moving average price of $52.03 and a two-hundred day moving average price of $53.21.

Sonova Company Profile

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.